Address
10 Sylvan Way
Parsippany, NJ 07054
United States of America (the)
Phone
973 822 7000
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
13800
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Kristin C. Peck | Chief Executive Officer & Director | 5.42M | 1971 |
| Roxanne Lagano | Executive Vice President, General Counsel & Corporate Secretary | 1.44M | 1965 |
| Robert J. Polzer | Scientific Advisor | 1.45M | 1969 |
| Kevin Esch | Executive Vice President and President of Research & Development | 1.52M | 1977 |
| Jamie Brannan | Executive Vice President & Chief Commercial Officer | 1.74M | 1973 |
| Wetteny N. Joseph | Executive Vice President & Chief Financial Officer | 1.8M | 1972 |
| Julie A. Fuller | Executive Vice President, Chief Human Resources Officer & Global Operations | 0 | 1973 |
| Keith Sarbaugh | Executive Vice President & Chief Digital and Technology Officer | 0 | 1979 |
| Steven Frank | Vice President of Investor Relations | 0 | N/A |
| Jeannette Ferran Astorga | Executive Vice President of Corporate Affairs & Chief Sustainability Officer | 0 | 1976 |
| Rimma Driscoll | EVP of Global Strategy, Portfolio Mktg. & Business Dev and Global BioDevices & Platinum Performance | 0 | 1973 |
| Nick Ashton | Executive Vice President and President of Global Manufacturing & Supply | 0 | 1974 |
| Jared Shriver | President of U.S. Operations | 0 | N/A |
Zoetis Inc. operates as a prominent global animal health enterprise, dedicated to the research, development, production, and marketing of advanced pharmaceuticals, biologicals, and diagnostic solutions. Its extensive product portfolio targets a broad spectrum of animals, encompassing livestock like cattle, pigs, poultry, fish, and sheep, as well as companion animals such as dogs, cats, and horses, serving both the United States and international markets. The company's offerings include a diverse range of vaccines, designed as biological preparations to prevent afflictions of the respiratory, gastrointestinal, and reproductive systems, or to stimulate a targeted immune response. It also provides anti-infectives that combat or inhibit the proliferation of bacteria, fungi, and protozoa, alongside parasiticides crucial for eradicating or preventing internal and external parasites, such as fleas, ticks, and various worms. Additionally, its pharmaceutical pipeline features products for pain and sedation, antiemetic solutions, reproductive health, and oncology. Zoetis also develops dermatology treatments for allergic skin conditions and atopic dermatitis, alongside medicated feed additives for livestock. Beyond therapeutics, Zoetis is a provider of comprehensive diagnostic tools. These include portable blood and urine analysis systems, point-of-care diagnostics, specialized instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitoring devices. Complementing these are other non-pharmaceutical solutions such as nutritional supplements, agribusiness services, biodevices, genetic testing, and advanced precision animal health technologies. The company distributes its extensive portfolio to a diverse client base, including veterinarians, livestock producers, and retail channels, often working with third-party veterinary distributors. This outreach is supported by its dedicated sales representatives and a team of technical and veterinary operations specialists. Established in 1952, Zoetis maintains its headquarters in Parsippany, New Jersey.